A Study to Evaluate Mesenchymal Stem Cells for Reducing Anastomotic Stenosis

Overview

Información sobre este estudio

The purpose of this study is evaluate the safety of allogeneic adipose derived mesenchymal stem cell (AMSC) use during hemodialysis arteriovenous fistula and arterial bypass creation and its effectiveness on improving access maturation and primary anastomotic patency.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Patient between 18 and 85 years old.
  • Patient currently planned for creation of an upper extremity AV fistula with suitable anatomy.
  • Ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures.
  • Life expectancy of at least 24 months.
  • If female, must be post menopausal or not able to have children.  Post-menopausal/non-child bearing status must be clearly documented in the medical record. If documentation of post-menopausal/non-child bearing status is not available then a pregnancy test must be performed.

Exclusion Criteria:

  • Malignancy or treatment for malignancy within the previous 6 months.
  • Immunodeficiency including AIDS / HIV or active autoimmune disease.
  • Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous intravascular thrombotic events.
  • Treatment with any investigational drug/ device within 60 days prior to study entry or any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs and the AVF.
  • History of failed organ transplant on immunosuppression.
  • Subjects with known active infection (infection which is being treated).

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Albert Hakaim, M.D.

Abierto para la inscripción

Contact information:

Mauricia Buchanan R.N.

(904) 953-2077

Buchanan.Mauricia@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20492294

Mayo Clinic Footer